"This acquisition accelerates the development of integrated sample processing capabilities for our technology, and aligns with our mission to reduce healthcare costs and improve clinical outcomes by providing innovative and affordable solutions to today's clinical laboratories," said Luminex CEO Patrick J. Balthrop. "The acquisition of GenturaDX builds on our strategic investments to date and positions the company to deliver ongoing growth by increasing our product portfolio, expanding our market opportunities and leveraging our leadership position."

Luminex expects the acquisition will add about $6 million in operating expenses this year, excluding acquisition-related expenses. Additional payments beyond the $50 million up front may be made as well, if GenturaDx meets future milestones or achieves product revenue targets.